"Cyclosporins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.
| Descriptor ID |
D003524
|
| MeSH Number(s) |
D04.345.566.235 D12.644.641.235
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclosporins".
Below are MeSH descriptors whose meaning is more specific than "Cyclosporins".
This graph shows the total number of publications written about "Cyclosporins" by people in this website by year, and whether "Cyclosporins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclosporins" by people in Profiles.
-
Hepatitis C virus replication compartment formation: mechanism and drug target. Gastroenterology. 2014 May; 146(5):1164-7.
-
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 01; 120(7):1010-7.
-
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
-
Modulation of Na+-Ca2+ exchanger expression by immunosuppressive drugs is isoform-specific. Mol Pharmacol. 2008 Apr; 73(4):1254-63.
-
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb 15; 106(4):830-8.
-
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301.
-
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9.
-
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002 Aug 15; 100(4):1224-32.
-
Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med. 2001; 52:299-318.
-
FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc. 1991 Dec; 23(6):3225-7.